Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Dr Reddy's Lab drops after quality issue delays semaglutide supplies
Dr Reddy's Laboratories tumbled 6.29% to Rs 1,263.90 after the company said commercial supplies of certain batches of its semaglutide product will be delayed following a quality-related issue involving the active pharmaceutical ingredient (API).
Cupid rebounds 6% after sharp fall as upgraded FY27 guidance boosts sentiment
Cupid shares rebounded nearly 6% after a sharp correction in the previous session, as investors turned positive following the company’s upgraded FY27 revenue guidance of Rs 660 crore. Strong Q1 momentum, a robust order book, expanding global opportunities, and growth across healthcare, personal care, and wellness businesses helped revive sentiment toward the stock.
Volumes soar at Acutaas Chemicals Ltd counter
Acutaas Chemicals Ltd clocked volume of 4 lakh shares by 10:46 IST on BSE, a 12.77 times surge over two-week average daily volume of 31312 shares
Natco Pharma gains nearly 3% on ₹2,500 crore South Africa investment plan
Natco Pharma has announced investments of nearly ₹2,500 crore in South Africa, including infusing ₹1,400 crore in its arm in the country with an aim to enter new geographies.
Sensex Today Rallies 541 Points | Nifty Above 24,000 | Bharti Airtel & Sun Pharma Top Gainers - Equitymaster
Sensex Today Rallies 541 Points | Nifty Above 24,000 | Bharti Airtel & Sun Pharma Top GainersEquitymaster
Sensex Today Rallies 541 Points | Nifty Above 24,000 | Bharti Airtel & Sun Pharma Top Gainers - Equitymaster
Sensex Today Rallies 541 Points | Nifty Above 24,000 | Bharti Airtel & Sun Pharma Top GainersEquitymaster
Peak XV nets 12 fold gain on K12 Techno after Vitruvian infuses ₹1,159 crore
Peak XV Partners has achieved a remarkable 12-fold return on its investment after a substantial ₹1,159 crore influx from Vitruvian Partners into K12 Techno Services. This deal catapults K12's valuation and highlights its rapid growth in India's booming education market.
Explained - Why Jefferies is bearish on Dr. Reddy's and Cipla but bullish on Mankind Pharma
Jefferies has mixed views on pharma stocks. It has an "underperform" rating on Dr Reddy's and Cipla, and a "buy" recommendation on Mankind Pharma.
Dr Reddy's flags quality issue in semaglutide batches, delays commercial supplies
Dr Reddy's Laboratories has announced a setback in the distribution of their semaglutide products attributed to out-of-specification batches associated with an active ingredient concern. The firm is actively investigating to identify the source of the problem and is implementing corrective strategies.
Dr. Reddy's Laboratories shares fall 3% on semaglutide batch concerns, supply delay
Dr. Reddy's also warned that until the issue is resolved, commercial supplies of the product will be delayed for a certain period of time, while also clarifying that there is no impact on patient safety or on the product's existing global regulatory filings.
Top fashion brands have a supply chain battle against extreme India heat
As Indian garment factories contend with soaring temperatures, worker efficiency and health have been jeopardised. Epic Group's facility in Odisha has introduced cutting-edge cooling technology to combat these challenges. Employees have reported substantial improvements in concentration and comfort in the climate-managed setting.
Aegis Logistics among 4 stocks that closed below VWAP
Four Nifty500 stocks, Balkrishna Industries, Aegis Logistics, PhysicsWallah and OneSource Specialty Pharma, closed over 3% below VWAP, highlighting bearish sentiment and weakening price momentum.